<?xml version="1.0" encoding="utf-8"?>
<Journal>
<Journal-Info>
<name>International Journal of Pharma and Bio Sciences</name>
<website>ijpbs.net</website>
<email>editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com</email>
</Journal-Info>
<article>
<article-id pub-id-type='other'>10.22376/ijpbs.2019.10.1.p1-12</article-id>
<issue_number>Volume 6 Issue 3</issue_number>
<issue_period>2015 (July - September)</issue_period>
<title>COMPARATIVE STUDY OF EPIDURAL 0.5% LEVOBUPIVACAINE AND EPIDURAL 0.5% LEVOBUPIVACAINE WITH DEXMEDETOMIDINE ON SENSORY BLOCKADE FOR PATIENTS UNDERGOING ELECTIVE INFRAUMBILICAL AND LOWER LIMB SURGERIES </title>
<abstract>Levobupivacaine , the pure S enantiomer of bupivacaine has emerged as a safe local anaesthetic than its racemic counterpart. Dexmedetomidine the novel selective alpha2 adrenergic agonist has several advantages when given through epidural route as an adjuvant. To compare plain 0.5% Levobupivacaine with Dexmedetomidine and 0.5% levobupivacaine epidurally for the time of onset of sensory blockade and its duration. 60 patients undergoing infraumblical and lower limb surgeries were randomized to two groups. Group A(n=30) received only Levobupivacaine 0.5% 20 ml epidurally. Group B(n=30) received 50 mcg of dexmedetomedine with Levobupivacaine 0.5% 20 ml epidurally. The time of onset of sensory blockade, maximum height of sensory blockade and duration of blockade were noted. Statistical work done by student t test and chi-square test and p lessThan  0.05% were taken to be significant. Dexmedetomidine fastens the onset of sensory blockade and the duration of blockade without any significant adverse effects. : We conclude that Dexmedetomidine can be used as an adjuvant to Levobupivacaine which fastens the onset and prolong the duration of sensory blockade.</abstract>
<authors>DR.ARUN POTHAN RAJ.V AND DR.NIRANJAN KUMAR</authors>
<keywords>Levobupivacaine, Dexmedetomidine, Sensory blockade.</keywords>
<pages>1264-1269</pages>
</article>
</Journal>
